Sarepta's already approved DMD therapy, Exondys 51, only increases dystrophin levels to less than 1% of that seen in healthy patients. Jerry Mendell, of Nationwide Children’s Hospital ...

Importantly, and unlike Sarepta's other three therapies, which are designed to treat patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53, and exon 45 ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

It’s bad form to compare performance of drugs in separate clinical trials, but results suggest that Viltepso helps patients produce more dystrophin than Sarepta’s rival Vyondys 53 (golodirsen).

Elevidys, developed by Sarepta Therapeutics, delivers a micro-dystrophin gene designed to compensate for the missing dystrophin-producing genes in patients with DMD. In the trial, "AAV gene ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Sarepta (SRPT) announced topline results from Part 2 of EMBARK, a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study ...

Sarepta’s net product revenue does not include ... mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for ...